Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified…
Study Finds Brain Training Also Helps Caregivers of Dementia Patients
SAN FRANCISCO, April 01, 2025 (GLOBE NEWSWIRE) -- While a particular brain…
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
March 21, 2025 17:05 ET | Source: Annovis Bio Inc. MALVERN, Pa.,…
Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left…
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimers Disease
February 13, 2025 08:00 ET | Source: NKGen Biotech The results from…
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio,…
Annovis Bio, Inc. Announces Proposed Public Offering
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis…
Perennial Alzheimer’s Care Village Xi’an Positioned as China’s First and the World’s Sixth Alzheimer’s Care Village
Integrated Western and Eastern medicine, coupled with non-drug intervention therapies, sets international…
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer’s Disease
Boca Raton, Florida, Nov. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:…
KFSHRC & Lilly Collaborate in Alzheimers Early Detection
RIYADH, Saudi Arabia, Nov. 03, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist…